Yuhan Past Earnings Performance

Past criteria checks 5/6

Yuhan has been growing earnings at an average annual rate of 2.8%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 5.5% per year. Yuhan's return on equity is 7.5%, and it has net margins of 8.2%.

Key information

2.8%

Earnings growth rate

2.0%

EPS growth rate

Pharmaceuticals Industry Growth	11.3%
Revenue growth rate	5.5%
Return on equity	7.5%
Net Margin	8.2%
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Yuhan makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A000105 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	2,008,841	165,686	384,162	197,701
30 Jun 24	1,893,119	147,849	385,446	146,919
31 Mar 24	1,860,529	124,466	378,998	130,975
31 Dec 23	1,858,984	133,993	370,027	119,920
30 Sep 23	1,872,336	88,109	365,050	117,355
30 Jun 23	1,820,811	76,045	350,511	114,124
31 Mar 23	1,808,041	101,446	355,579	111,826
31 Dec 22	1,775,847	95,144	356,575	107,103
30 Sep 22	1,749,315	74,669	359,069	116,405
30 Jun 22	1,769,245	97,836	362,073	112,866
31 Mar 22	1,719,630	97,911	355,095	108,107
31 Dec 21	1,687,810	102,583	346,977	106,677
30 Sep 21	1,725,261	98,128	350,567	121,027
30 Jun 21	1,703,475	97,833	333,638	128,767
31 Mar 21	1,685,623	97,578	321,279	141,056
31 Dec 20	1,619,865	192,761	309,459	142,634
30 Sep 20	1,552,188	184,730	292,514	124,020
30 Jun 20	1,504,765	168,667	292,671	109,357
31 Mar 20	1,448,677	140,227	291,603	96,264
31 Dec 19	1,480,354	40,006	298,249	96,900
30 Sep 19	1,500,782	44,230	295,958	84,846
30 Jun 19	1,497,130	41,438	289,460	86,652
31 Mar 19	1,523,954	52,333	285,113	81,152
31 Dec 18	1,518,823	57,481	272,199	74,067
30 Sep 18	1,481,906	70,146	260,112	78,217
30 Jun 18	1,482,034	84,572	255,011	72,563
31 Mar 18	1,450,870	100,288	254,545	70,132
31 Dec 17	1,462,248	109,034	251,733	71,435
30 Sep 17	1,434,749	139,325	247,128	63,536
30 Jun 17	1,417,835	137,434	242,253	60,608
31 Mar 17	1,395,518	139,440	233,210	57,434
31 Dec 16	1,320,797	161,249	228,048	52,667
30 Sep 16	1,274,011	134,997	229,655	50,435
30 Jun 16	1,223,925	155,819	221,368	48,078
31 Mar 16	1,163,130	152,682	209,371	43,881
31 Dec 15	1,128,731	126,047	206,756	39,016
30 Sep 15	1,097,229	118,104	199,135	34,597
30 Jun 15	1,046,716	98,362	199,297	30,754
31 Mar 15	1,031,875	94,628	202,271	31,270
31 Dec 14	1,017,492	90,948	202,259	30,915
30 Sep 14	1,007,109	95,434	200,307	31,018
30 Jun 14	970,253	87,696	192,807	31,896
31 Mar 14	953,191	83,863	193,993	31,378
31 Dec 13	943,609	86,461	192,515	32,027

Quality Earnings: A000105 has high quality earnings.

Growing Profit Margin: A000105's current net profit margins (8.2%) are higher than last year (4.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A000105's earnings have grown by 2.8% per year over the past 5 years.

Accelerating Growth: A000105's earnings growth over the past year (88%) exceeds its 5-year average (2.8% per year).

Earnings vs Industry: A000105 earnings growth over the past year (88%) exceeded the Pharmaceuticals industry 22.3%.

Return on Equity

High ROE: A000105's Return on Equity (7.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 19:11
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yuhan Corporation is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Young-Ah Han	BofA Global Research
Seohyun Lee	Citigroup Inc
Hyonseok Kim	CLSA